Product Menu & Molecule Stratification
Bottom line for this section
Of the user's 22-peptide menu, ONLY NAD+ injectable and topical GHK-Cu pass a 2026 clean compliance screen as Tier 1 launch products today; Tier 2 (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax) requires the July 23-24 2026 PCAC outcome AND downstream FDA rulemaking before adding; Tier 3 (CJC-1295, Ipamorelin) requires extraordinary documented patient-specific clinical justification and is RECOMMENDED SKIP per the Tactus Health compliance posture; Branded Rx (PT-141 via Vyleesi where indication overlaps) is the only PT-141 pathway; FULLY AVOID (Tesamorelin compounded, Melanotan 1, Melanotan 2, SS-31, Retatrutide, BPC/TB-4 combo, GLOW, K-L-O-W combo); RUO-or-skip and recommended SKIP (Selank, ARA-290).
Research
Of the 22 peptides on the user's proposed menu, only a small handful pass a 2026 evidence-based compliance screen for a US telehealth venture that already has a prescribing physician asset and is choosing between four pathways (clean 503A, branded Rx, RUO, or skip). Three peptides have FDA-approved branded products that subject any compounded form to the 'essentially a copy' attack vector: PT-141 (Vyleesi, NDA 210557, approved June 21 2019), Melanotan 1 / afamelanotide (Scenesse, NDA 210797, approved October 8 2019), and Tesamorelin (Egrifta, application number 022505 (BLA) approved November 2010; Egrifta WR F8 approved March 2025). A fourth peptide on the list now has an FDA-approved version that emerged after the user's brief was drafted: SS-31 / Elamipretide (FORZINITY, NDA 215244, accelerated approval September 19 2025 for Barth syndrome — ultra-narrow ~150-patient US population). Six peptides plus DSIP (BPC-157, TB-4/TB-500, KPV, MOTS-C, Semax, Epitalon, DSIP/Emideltide) are in regulatory limbo with PCAC review July 23-24 2026. Three (CJC-1295, Ipamorelin, Selank) sit in deeper limbo: removed from Category 2 in September 2024 with NO further FDA review timeline. Retatrutide is in Eli Lilly's Phase 3 TRIUMPH program with NDA filing targeted Q4 2026, creating both manufacturer-litigation exposure and pending essentially-a-copy risk. ARA-290 / Cibinetide is a stranded molecule — Araim Pharmaceuticals has closed, no active IND, no FDA path. Melanotan 2 has UK MHRA ban (2019), Australian TGA infringement actions, FDA warning letters since 2007, and pending Feb 2027 PCAC review. GHK-Cu has split status: non-injectable forms appear on 503A Category 1, while injectable forms are pending Feb 2027 PCAC. NAD+ is a coenzyme (not technically a peptide) with no FDA-approved commercial equivalent — the cleanest near-term Tier 1 candidate. Direct fetches of Eden Health, Good Life Meds, and Tactus Health menus reveal that even the largest multi-peptide platform operators currently sell only sermorelin, NAD+, GHK-Cu Foam (topical), PT-141 (Branded Rx only via Vyleesi), and GLP-1s — NONE sell BPC-157, KPV, MOTS-C, CJC-1295, Ipamorelin, Tesamorelin, Epitalon, DSIP, Semax, Selank, or Melanotan. The hybrid Rx+RUO business model is strongly contraindicated: FDA's April 2026 warning letter wave against seven peptide vendors explicitly characterized RUO disclaimers as a 'ruse' and applied the Intended Use Doctrine, the DOJ secured the Tailor Made Compounding guilty plea ($1.79M forfeiture, October 2020) for distribution of unapproved drugs including BPC-157, CJC-1295, DSIP, Epitalon, Ipamorelin, Selank, and Semax, and Mastercard's June 2025 BRAM update (GLB 11691.1) terminates accounts and freezes funds 90-180 days for merchants mixing prescription compounded products with RUO sales.
Key facts
PT-141 (bremelanotide) has an FDA-approved branded version: Vyleesi, NDA 210557, approved June 21, 2019, manufactured by Palatin Technologies (licensed in North America originally to AMAG Pharmaceuticals). Indication: treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Compounding PT-141 outside this indication triggers the essentially-a-copy attack under FDCA 503A(b)(1)(D) unless documented patient-specific clinical justification exists.
Melanotan 1 (afamelanotide) has an FDA-approved branded version: Scenesse, NDA 210797, approved October 8, 2019, manufactured by Clinuvel Pharmaceuticals Limited. Indication: prevent painful skin damage from sun exposure in adult patients with history of phototoxic reactions from erythropoietic protoporphyria (EPP). Administered as 16 mg controlled-release subcutaneous implant providing protection for up to 60 days. Structurally distinct from the unapproved black-market Melanotan 2.
Tesamorelin has an FDA-approved branded version: Egrifta, application number 022505 (BLA), approved November 10, 2010, manufactured by Theratechnologies Inc. Indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Second-generation F8 formulation, EGRIFTA WR (sBLA approved March 2025), reduces administration volume by more than half. Two distinct FDA-approved tesamorelin formulations now exist — compounding tesamorelin triggers essentially-a-copy against both approved versions.
SS-31 / Elamipretide has an FDA-approved branded version that emerged after the user's brief was drafted: FORZINITY (elamipretide injection), NDA 215244, accelerated approval granted September 19, 2025, manufactured by Stealth BioTherapeutics. Indication: improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg. Dose: 40 mg subcutaneous once daily. Approval based on TAZPOWER trial intermediate endpoint. Barth syndrome affects approximately 150 individuals in the United States — an ultra-rare indication that does NOT overlap any plausible peptide-wellness venture's patient population. The user's brief assumed SS-31 was post-CRL Phase 3; this is now incorrect.
Retatrutide (Eli Lilly's GLP-1/GIP/glucagon triple agonist, the actual molecule sometimes marketed colloquially as 'GLP-3') reported positive Phase 3 TRIUMPH-1 topline results in October 2025: participants on 12 mg dose lost an average 70.3 lbs (28.3%) over 80 weeks. Eli Lilly is targeting Q4 2026 as earliest plausible NDA filing window, with potential approval in 2027. Compounding retatrutide places the venture in direct manufacturer-litigation crosshairs — Eli Lilly already sued four compounders for tirzepatide in April 2025.
ARA-290 / Cibinetide is a stranded molecule. Araim Pharmaceuticals, the clinical-stage sponsor that took the compound through Phase 2 trials for sarcoidosis-associated small-fiber neuropathy and diabetic macular edema and received FDA orphan drug designation, has closed. No active IND exists as of April 2026, no Phase 3 trials are registered on ClinicalTrials.gov, and the compound has no current regulatory pathway to approval without a new sponsor. ARA-290 was never on any FDA 503A bulks list and has no clear lawful 503A path.
Melanotan 2 is the subject of converging international enforcement. The FDA issued its first warning letter to a Melanotan II marketer (Melanocorp) on or about August 30, 2007, with reiteration in 2024 that Melanotan products marketed for human use are unapproved new drugs and misbranded cosmetics. The UK MHRA banned both Melanotan I and Melanotan II in 2019, making sale, supply, and possession illegal. Australia's TGA issued 27 infringement notices totaling AUD $101,412 to a NSW individual for unlawful supply in contravention of the Therapeutic Goods Act 1989. Melanotan II is ALSO on the FDA's February 2027 PCAC review agenda — both 'globally banned' and 'pending FDA review for compounding' are simultaneously true.
FDA placed BPC-157, ipamorelin acetate, AOD-9604, and kisspeptin-10 in Category 2 of the interim 503A bulks list in September 2023 — the designation reserved for substances with 'significant safety risks' that triggers FDA or state board enforcement on compounding. None of these peptides were ever on Category 1.
FDA announced on April 15-16, 2026 the removal of 12 peptides from Category 2 of the interim 503A bulks list pending PCAC review at two separate meetings. The seven peptides under July 23-24, 2026 review: BPC-157, KPV, TB-500 (thymosin beta-4), MOTs-C, DSIP/Emideltide, Semax, Epitalon. The five peptides under February 2027 review: GHK-Cu (injectable forms), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, Mechano Growth Factor, Pegylated PEG-MGF. Removal from Category 2 does NOT place these substances on Category 1 — they remain in a non-permitted regulatory limbo until PCAC review and FDA rulemaking.
On September 27, 2024, FDA removed CJC-1295 (all forms), AOD-9604, ipamorelin acetate, thymosin alpha-1, and Selank from Category 2 of the interim 503A bulks list following nominator withdrawals connected to the Evexias Medical Group / Farmakeio settlement. CJC-1295, ipamorelin, and Selank were NOT placed on Category 1 and are NOT on the July 2026 or February 2027 PCAC agenda — they exist in a deeper limbo with no scheduled FDA review.
GHK-Cu (copper peptide) has split regulatory status. Topical/non-injectable GHK-Cu (cosmetic-grade) is described as a Category 1 substance under the interim 503A bulks list ('vasoactive intestinal peptide and GHK-Cu (non-injectable)' per Fagron Academy 2023). Injectable GHK-Cu is scheduled for FDA's PCAC review on February 2027. The cosmetic-pathway non-injectable form is the only Tier 1 candidate among the user's 22-peptide list besides NAD+. Eden Health's GHK-Cu Foam (topical, for hair growth) is the live precedent operator product.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not technically a peptide. It has no FDA-approved branded commercial equivalent — eliminating the 'essentially a copy' attack vector under 503A(b)(1)(D). Multiple operators sell injectable NAD+ legally as a compounded preparation: Eden Health ($186-246/mo), Good Life Meds (verified live menu — Microdose GLP-1 + NAD+ injections + nasal spray + Sermorelin are the entire injectable peptide-adjacent catalog). NAD+ is the cleanest near-term Tier 1 launch candidate.
Direct fetch of Eden Health's menu on May 22 2026 confirms Eden offers compounded GLP-1 (semaglutide injection + tirzepatide injection), Sermorelin (injection + oral tablet), NAD+ (injection + face cream + nasal spray), GHK-Cu Foam (topical, hair growth for men and women), MIC+B12 injection, and hair products. Eden does NOT offer BPC-157, TB-500, KPV, MOTS-C, CJC-1295, Ipamorelin, Tesamorelin, Epitalon, DSIP, Semax, Selank, or Melanotan — a strong signal that even the largest multi-peptide platform operator avoids the entire Category 2 / removed-from-Cat-2 inventory.
Direct fetch of Good Life Meds' menu on May 22 2026 confirms its entire injectable peptide-adjacent catalog is: Sermorelin, NAD+ Injections, NAD+ Nasal Spray, and Microdose GLP-1 — plus GLP-1 brand options, sexual health (sildenafil/tadalafil), hair products, and B12/glutathione. Good Life Meds does NOT offer BPC-157, TB-500, PT-141, KPV, MOTS-C, CJC-1295, Ipamorelin, Tesamorelin, GHK-Cu, Semax, Selank, Melanotan, DSIP, or Epitalon.
Tactus Health (tactushealth.com) is positioned as the compliance-flagship operator and explicitly prescribes ONLY sermorelin and PT-141 — 'the two legally compoundable, clinically supported peptides' per the operator. Tactus actively refuses to prescribe BPC-157, CJC-1295, and ipamorelin because they 'are on the FDA's Category 2 bulk drug substances list, which prohibits their compounding for human use.' Even Tactus does not engage the user's wellness peptides — they prescribe two molecules total.
DOJ secured a federal criminal guilty plea from Tailor Made Compounding LLC and its founder Jeremy Delk in October 2020. Tailor Made pleaded guilty to one count of distributing unapproved new drugs between October 2018 and April 2020. The substances explicitly named in the plea: BPC-157, Cerebrolysin, CJC-1295, DSIP, Epitalon, GW 501516, Ipamorelin, LGD-4033, LL-37, Melanotan II, MK-677, PEG-MGF, Selank, and Semax. Judge Van Tatenhove sentenced TMC to three years' probation and ordered forfeiture of $1,788,906.82. This establishes federal CRIMINAL prosecution — not just civil warning letters — against peptide distributors covering nearly every research peptide on the user's menu.
FDA issued seven warning letters dated March 31, 2026 (published April 7, 2026) against research-peptide vendors that used RUO disclaimers: Pink Pony Peptides (Lovega LLC, Wellington FL), Mile High Compounds LLC (Clifton CO), Prime Sciences (Scottsdale AZ), Gram Peptides (Rancho Santa Fe CA), PekCura Labs (Pensacola FL), FormPour (Canton MI), and Guangzhou Huli Technology dba Fantasy Face (Chicago IL). The Gram Peptides letter contained verbatim: 'Despite statements on your product labeling marketing your products for Research Use Only, evidence obtained from your website establishes that your products are intended to be drugs.' FDA also tied bacteriostatic water co-sale to intended-use evidence.
FDA's official position on the RUO disclaimer, restated across multiple 2024-2026 warning letters: research-use-only labeling is 'a ruse to avoid FDA scrutiny for selling misbranded and adulterated products in violation of the FD&C Act.' The legal theory is the Intended Use Doctrine — FDA examines actual marketing (website language, customer communications, product positioning, related-product co-sale patterns), NOT just the label disclaimer. Named vendors warned in December 2024 alone: Prime Peptides, Xcel Peptides, SwissChems, Summit Research Peptides.
Mastercard's June 2025 BRAM (Business Risk Assessment and Mitigation) Program update — bulletin GLB 11691.1 — explicitly flags 'research peptides, nutraceuticals, and unapproved pharmaceuticals' as high-risk merchant categories. Common BRAM red flags include 'using non-compliant phrases like GLP-1 for weight loss on unapproved products,' 'selling research peptides alongside bodybuilding or weight loss claims,' and 'offering bundles that include scheduled or prescription-only ingredients.' Mastercard's automated detection terminates accounts and freezes funds, typically for 90-180 days. A hybrid Rx + RUO merchant fits multiple BRAM red flags simultaneously.
Insurance carrier underwriting categorically excludes coverage for unapproved medications. Standard medical-malpractice policies contain explicit exclusions for 'experimental' or 'investigational' treatments and may exclude class actions or administrative hearings related to off-label drug use. For a hybrid Rx+RUO entity, the RUO arm would not be covered under any standard medical-malpractice product (no patient relationship → no medical care → no E&O coverage), AND the existence of the RUO channel becomes a material misrepresentation risk that can void the prescription-side med-mal policy.
The 'GLOW' combination on the user's menu is the multi-peptide blend BPC-157 + TB-500 + GHK-Cu (typically marketed as a recovery / wound-healing stack). Each component peptide inherits its own regulatory status — the combination is at best as compoundable as its most restricted member. Per April 2026 status: BPC-157 and TB-500 are pending July 23-24 2026 PCAC; GHK-Cu (if injectable) is pending February 2027 PCAC. The injectable GLOW combination is therefore not lawfully compoundable today. The user's 'K-L-O-W' / 'KPV-L-O-W' nomenclature is non-standard and varies by source (typically KPV + GHK-Cu + BPC-157 + TB-500); composition ambiguity itself is a regulatory red flag.
Telehealth providers that DO openly prescribe Semax and Selank as of 2026 are smaller specialty clinics (Better Med Spa Illinois, Iowa IV, Nava Health) rather than national operators. The April 2026 FDA reclassification announcement places Semax on the July 23-24 2026 PCAC agenda but does NOT include Selank — Selank's regulatory status is unchanged from the September 2024 Evexias-era removal-without-Cat-1-placement limbo. Selank specifically has no FDA review timeline and is high-risk to offer.
FDA's April 1, 2026 clarification states a compounded preparation is 'essentially a copy' of a commercially available drug when it has the same API at a strength within 10% of the commercial product and uses the same route of administration. Applied to the user's menu: any compounded PT-141 within 10% of Vyleesi's 1.75 mg dose, any compounded Tesamorelin within 10% of Egrifta's 2 mg/day, any compounded Afamelanotide within 10% of Scenesse's 16 mg implant, and any compounded Elamipretide within 10% of FORZINITY's 40 mg/day — all trigger essentially-a-copy without individualized patient-specific clinical-difference documentation.
FTC approved a final order against telehealth weight-loss provider NextMed on December 3, 2025, securing $150,000 in monetary relief and naming Robert Epstein and Frank Leonardo individually. The order targeted unsubstantiated weight-loss efficacy claims, fake testimonials, distorted consumer reviews, undisclosed subscription costs ($138-188/month that did NOT include the GLP-1 drug or required labs), and failure to obtain express informed consent for recurring debits. This is the FOURTH enforcement-precedent stacking against a hybrid Rx + RUO peptide telehealth model — alongside (1) Tailor Made Compounding DOJ guilty plea covering 8 of the user's 22 peptides + 3 combos, (2) FDA's March 31 2026 Gram Peptides 'RUO is ruse' Intended Use Doctrine warning letter, and (3) Mastercard's June 2025 BRAM GLB 11691.1 account-termination + 90-180 day fund freeze. The NextMed action is targeted at telehealth-specific deceptive marketing rather than peptide chemistry, but its $150K monetary penalty and individual-defendant naming make it directly relevant precedent for any peptide-telehealth marketing strategy under FTC Section 5 + the December 2022 Health Products Compliance Guidance.
Tradeoffs
Tier 1 minimal launch (NAD+ + GHK-Cu topical) vs full 22-peptide menu launch
Tier 1 only — NAD+ injectable + GHK-Cu topical, defer everything else
Pro: Both products have no FDA-approved branded equivalent (no essentially-a-copy attack on NAD+; GHK-Cu non-injectable on Cat 1); Both have proven live-operator precedent (Eden, Good Life Meds, multiple smaller clinics); Payment processors will underwrite alongside standard telehealth without BRAM red flags; Standard medical-malpractice insurance underwriting holds; Avoids July 23-24 2026 PCAC outcome dependency
Con: Materially narrower revenue mix; cannot compete on breadth; Sermorelin (not on user's list but obvious complementary addition) carries FTC anti-aging marketing risk per §2 + §6; Forfeits brand differentiation through curated specialty menu
Full 22-peptide menu launch in 2026 (user's stated intent)
Pro: Maximum breadth and brand differentiation in wellness/biohacker segment; Captures patient demand currently going to grey-market RUO vendors
Con: 11 of 22 peptides are not lawfully compoundable today (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax pending July 2026 PCAC + downstream rulemaking; CJC-1295, Ipamorelin, Selank — no FDA review timeline) — placing venture in Tailor Made-style criminal-prosecution risk zone; 5 of 22 have FDA-approved branded versions or are in branded development (PT-141/Vyleesi, Melanotan 1/Scenesse, Tesamorelin/Egrifta, SS-31/FORZINITY, Retatrutide/Lilly Phase 3) — essentially-a-copy + manufacturer-litigation exposure; 3 of 22 have no clean compoundable OR RUO pathway (Selank, ARA-290, DSIP if framed via RUO); Melanotan 2 has international ban precedent + FDA enforcement history + pending Feb 2027 PCAC; All risks compound: each unlawful peptide is independent evidence of intent-to-distribute-unapproved-drugs; No major operator (Eden, Mochi, Henry, Good Life, Tactus, MEDVi, Willow, Noom, Ro) sells more than ~3 wellness peptides; user's 22 would be broadest menu in market — wrong direction
Branded Rx only (Vyleesi for PT-141; Egrifta for Tesamorelin) vs include compounded versions of FDA-approved peptides
Branded Rx only — prescribe Vyleesi, Egrifta, Scenesse, FORZINITY as appropriate; never compound
Pro: Zero essentially-a-copy exposure — manufacturer cannot bring 503A claim; Insurance reimbursement pathways possible (especially Egrifta for HIV-lipodystrophy, FORZINITY for Barth syndrome — both narrow); Payment processors underwrite branded Rx telehealth at standard rates; Standard medical-malpractice coverage applies without endorsement
Con: Vyleesi list price $250-300/dose retail vs $10-30/dose compounded; Egrifta + FORZINITY indications ultra-narrow (HIV-lipodystrophy, Barth syndrome) — patient pool tiny; Scenesse requires implant procedure not all telehealth physicians can perform; Forfeits dose/route-not-commercially-available carve-out
Include compounded versions of FDA-approved peptides under documented carve-outs
Pro: Larger margin per Rx; Some operators (Mochi, Henry, MEDVi) have made this work for GLP-1s using documented patient-specific clinical-difference framing
Con: Active FDA enforcement campaign on essentially-a-copy products — 50+ warning letters Sept 2025, 30 more Feb 2026; Manufacturer-litigation exposure (Lilly v. Mochi/Henry/Willow/Fella ongoing); DOJ referral risk (HHS referred Hims to DOJ Feb 6 2026); Payment processor freeze risk (Stripe/PayPal/Square reject; Mastercard BRAM); Patient-specific documentation burden per Rx; cost savings doesn't qualify
Include CJC-1295 + Ipamorelin (permanent limbo, no FDA review timeline) vs skip them entirely
Include CJC-1295 + Ipamorelin with documented patient-specific clinical justification
Pro: Both are popular growth-hormone-secretagogue peptides in wellness/biohacker segment; Removed from Category 2 in September 2024 (not currently designated 'significant safety risk'); Some smaller telehealth/medspa operators continue to prescribe
Con: Neither has ever been on Category 1 — never lawfully compoundable; Removed from Cat 2 in Sept 2024 with NO subsequent PCAC review scheduled — no regulatory pathway, no timeline; Jan 7 2025 final interim guidance closed 'interim eligibility while under review' pathway; Tactus Health (compliance-flagship) explicitly refuses to prescribe; Tailor Made DOJ plea covered both CJC-1295 and Ipamorelin — direct criminal-prosecution precedent; FTC growth-hormone / anti-aging marketing exposure is highest enforcement category
Skip CJC-1295 + Ipamorelin until and unless FDA places them on Category 1
Pro: Aligns with Tactus Health's compliance-flagship posture; Eliminates the highest-criminal-precedent peptides from the menu; Reduces FTC growth-hormone marketing risk
Con: Foregoes wellness/biohacker growth-hormone-secretagogue demand; Sermorelin alone covers some but not all of this demand
Pure Rx telehealth vs hybrid Rx + RUO research-peptide model
Pure Rx telehealth — physician prescription, 503A compounding pharmacy, no RUO channel
Pro: Single regulatory posture (FDA + state board + medical malpractice); Standard medical-malpractice insurance underwriting holds; Payment processors can underwrite under LegitScript Healthcare Merchant Certification; No exposure to RUO pretextuality enforcement (FDA's 'ruse' theory + Intended Use Doctrine); Aligned with every major live operator in §1
Con: Forfeits wellness peptides that have no clean Rx pathway (BPC-157, KPV, MOTS-C, etc.); Cannot scale to grey-market biohacker price points; Forfeits some patient acquisition channels
Hybrid Rx + RUO — telehealth prescription arm AND research-use-only direct-sales arm
Pro: Captures both regulated patient demand and grey-market research-buyer demand; Higher revenue per dollar of patient acquisition
Con: RUO pretextuality is established FDA + DOJ enforcement theory — Tailor Made $1.79M forfeiture + criminal plea; April 2026 seven-vendor warning letter wave with Gram Peptides quote: 'Despite statements...for Research Use Only, evidence obtained from your website establishes that your products are intended to be drugs.'; Mastercard BRAM GLB 11691.1 specifically flags 'selling research peptides alongside bodybuilding or weight loss claims' and 'offering bundles that include scheduled or prescription-only ingredients' — account termination + 90-180 day fund freeze; Insurance underwriting fails: RUO arm not coverable under medical-malpractice; existence of RUO arm becomes material misrepresentation that can void Rx-side med-mal policy; Single regulatory event collapses both businesses simultaneously; Existing patient testimonials in Rx arm become 'intended use' evidence against RUO arm; Banking partners refuse multi-channel hybrid sellers post-CFPB / OCC supervisory guidance; No major live operator in §1 runs a hybrid model — unanimous market signal is don't
"Of the user's 22-peptide menu, ONLY NAD+ injectable and topical GHK-Cu pass a 2026 clean compliance screen as Tier 1 launch products today; Tier 2 (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax) requires the July 23-24 2026 PCAC outcome AND downstream FDA rulemaking before adding; Tier 3 (CJC-1295, Ipamorelin) requires extraordinary documented patient-specific clinical justification and is RECOMMENDED SKIP per the Tactus Health compliance posture; Branded Rx (PT-141 via Vyleesi where indication overlaps) is the only PT-141 pathway; FULLY AVOID (Tesamorelin compounded, Melanotan 1, Melanotan 2, SS-31, Retatrutide, BPC/TB-4 combo, GLOW, K-L-O-W combo); RUO-or-skip and recommended SKIP (Selank, ARA-290). Even a Tier 1+2 menu would still be selling MORE peptides than Eden's 3-SKU live menu — that's a marketing/positioning consideration. The hybrid Rx+RUO model is strongly recommended AGAINST per three converging precedents (Tailor Made Compounding $1.79M DOJ forfeiture, FDA's March 31 2026 Gram Peptides 'ruse' characterization, Mastercard's June 2025 BRAM GLB 11691.1 account termination)."
Recommendation
LAUNCH WEEK 1: NAD+ injectable (500mg + 1000mg dose tiers, Eden $186-246/mo benchmark), GHK-Cu topical Foam (Eden precedent, men + women, hair growth indication), and if your prescribing physician is comfortable, sermorelin under the §2 Geref-component pathway (Tactus precedent). If patient indication overlaps, also dispense branded Egrifta (HIV-lipodystrophy), branded Vyleesi (premenopausal HSDD), branded Scenesse (EPP — implant requires special procedure), branded FORZINITY (Barth syndrome — ultra-narrow). DEFER UNTIL POST-PCAC + RULEMAKING (12-36 months): BPC-157, TB-4/TB-500, KPV, MOTS-C, Epitalon, DSIP/Emideltide, Semax — set calendar reminder for July 25 2026 + 14 days to evaluate PCAC outcome. RECOMMENDED SKIP (Tier 3 / RUO-or-skip): CJC-1295, Ipamorelin (Tailor Made DOJ precedent + Tactus refusal + permanent limbo); Selank (deeper limbo with no PCAC review); ARA-290 (stranded molecule, no sponsor). FULLY AVOID: Melanotan 2 (UK + Australia + FDA enforcement converging), Compounded Tesamorelin (off-label promotion + essentially-a-copy + FTC anti-aging triple risk), Melanotan 1 (only practical via Scenesse implant), SS-31 outside Barth syndrome (zero indication overlap), Retatrutide / 'GLP-3' (Lilly Phase 3 + imminent NDA filing + 'GLP-3' framing is FDA/FTC attractor), BPC/TB-4 combo and GLOW/K-L-O-W combinations (inherit worst-member status + composition ambiguity). DO NOT operate a hybrid Rx + RUO model — Tailor Made Compounding DOJ guilty plea (Oct 2020, $1.79M forfeiture, criminal counts), FDA March 31 2026 Gram Peptides warning letter ('Despite statements...for Research Use Only, evidence obtained from your website establishes that your products are intended to be drugs'), and Mastercard's June 2025 BRAM update (GLB 11691.1, 90-180 day fund freeze) are three independent contraindications. Even with a Tier 1+2 menu, the user's venture would still be selling MORE peptides than Eden's 3-SKU live menu — that's a marketing/positioning consideration: a curated 5-7 SKU specialty menu (matching Eden) is the upper bound that the live operator landscape proves can scale; a 12+ SKU menu would be the broadest in the market and an enforcement attractor in itself.
Steel-manned counter
The strongest TRUE counter to the Tier-1-only conservative posture is that a sophisticated founder with documented patient-specific Rx framing — modeled on Mochi's B12-combination structure for compounded tirzepatide or Henry Meds' oral-tablet dose/route carve-out — could capture broader market share including some Tier 2 wellness peptides today (BPC-157, KPV with allergy/dose-route/combination framing) at higher revenue and acceptable enforcement-risk pricing. Tactus Health's 2-SKU floor (sermorelin + PT-141) is a quality benchmark for compliance defensibility, but Eden's 5-7 SKU live menu (NAD+ injection + cream + nasal spray + sermorelin + MIC+B12 + GHK-Cu Foam + GLP-1) demonstrates that a curated specialty menu can scale without minimum-breadth dogma. Mochi's continued operation as a named Eli Lilly defendant — and Hims's recovery to FY2026 $2.8-3.0B revenue + $275-350M adjusted EBITDA guidance after exiting compounded GLP-1 — show that risk-tolerant operators with sophisticated MSA + carve-out documentation continue to grow. The failed-operator side (Tailor Made Compounding's 2020 plea covering 8 of 22 menu peptides + 3 combination products) remains the strongest precedent against pre-PCAC Tier 2 inclusion of CJC-1295/Ipamorelin/Selank, but Tier 2 peptides scheduled for July 23-24 2026 PCAC (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax) may be defensible TODAY under documented patient-specific clinical-difference framing per Mochi/Henry precedent — and waiting 12-36 months for PCAC + rulemaking forfeits first-mover positioning that more risk-tolerant competitors will capture.
| Feature | FDA approved? (Y/N + brand) | 503A bulks-list status (May 2026) | Manufacturer / litigation risk | Live operators selling (named) | Bucket recommendation | Notes |
|---|---|---|---|---|---|---|
| 1. BPC-157 | No | Was Cat 2 Sept 2023; removed April 15 2026; PCAC review July 23-24 2026; not lawfully compoundable | None — no manufacturer in late-stage development | None among Eden / Mochi / Henry / Good Life / Tactus / MEDVi / Willow / Noom / Ro | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Named in Tailor Made DOJ plea Oct 2020. Most popular research-peptide globally; demand exists but no lawful path today. |
| 2. TB-4 (Thymosin Beta-4) — same molecule as TB-500 | No | Was Cat 2 Sept 2023 (as thymosin beta-4); removed April 15 2026; PCAC review July 23-24 2026 (as TB-500); not lawfully compoundable | None — no manufacturer in late-stage development | None among major operators | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | TB-4 = TB-500 = thymosin beta-4 — single molecule, multiple market names. Treat as one product, not two. |
| 3. BPC/TB-4 Combo | No | Inherits worst of components: both pending July 2026 PCAC; not lawfully compoundable | None — no manufacturer in late-stage development | None — no major operator sells this combo | TIER 2 — add only if AND when BOTH BPC-157 and TB-4 receive favorable PCAC + Cat 1 rulemaking | Combination products inherit the most-restricted member's regulatory status; double documentation burden. |
| 4. KPV | No | Was Cat 2 Sept 2023; removed April 15 2026; PCAC review July 23-24 2026; not lawfully compoundable | None — no manufacturer in late-stage development | None among major operators | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Smaller demand vs BPC-157; anti-inflammatory positioning has FTC substantiation risk. |
| 5. ARA-290 (Cibinetide) | No — never approved | Never on any FDA bulks list (Cat 1 or Cat 2); no PCAC review scheduled | STRANDED — Araim Pharmaceuticals closed; no active IND; no Phase 3; no current FDA pathway | None — no major operator sells | RUO-OR-SKIP — RECOMMEND SKIP — neither Rx path nor RUO path is defensible | Even the RUO path is hostile: April 2026 seven-vendor wave shows FDA reading website context regardless of disclaimer. |
| 6. SS-31 (Elamipretide) | YES — FORZINITY (Stealth BioTherapeutics), NDA 215244, accelerated approval Sept 19 2025 | Approved branded version exists; compounding triggers essentially-a-copy under 503A(b)(1)(D) | Stealth BioTherapeutics is the manufacturer; would have litigation standing for essentially-a-copy claims | None — no major peptide-wellness operator sells | FULLY AVOID — Barth syndrome indication is ultra-narrow (~150 US patients) and does NOT overlap peptide-wellness venture target population; user's brief characterization of SS-31 as 'manufacturer Phase 3' is outdated | Approved AFTER user's brief was drafted. Patient population zero overlap; brand impractical to dispense as peptide-wellness product. |
| 7. MOTS-C | No | Was Cat 2 Sept 2023; removed April 15 2026; PCAC review July 23-24 2026; not lawfully compoundable | None — no manufacturer in late-stage development | None among major operators | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Mitochondrial-derived peptide; emerging research interest but no FDA path until PCAC + rulemaking. |
| 8. NAD+ (coenzyme, not technically a peptide) | No FDA-approved branded version (no essentially-a-copy attack vector) | Coenzyme — outside 503A peptide bulks list framework; compounded under standard 503A non-peptide pharmacy practice | No manufacturer litigation risk | Eden Health ($186-246/mo), Good Life Meds (verified live menu), multiple smaller clinics | TIER 1 — LAUNCH IMMEDIATELY | Cleanest near-term Tier 1 candidate on the list. Cosmetic-pathway NAD+ topical and nasal spray are even more conservative. |
| 9. GHK-Cu (Copper peptide) | No FDA-approved branded version | SPLIT STATUS — non-injectable / topical is Category 1 (Sept 2023 list); INJECTABLE is pending Feb 2027 PCAC | No manufacturer litigation risk | Eden Health offers GHK-Cu Foam (topical, hair growth); injectable not offered by any major operator | TIER 1 (topical / non-injectable) — LAUNCH IMMEDIATELY; TIER 2-deferred (injectable) — wait for Feb 2027 PCAC + downstream rulemaking | Eden's GHK-Cu Foam is live precedent. Cosmetic-pathway is the entry point. |
| 10. Epitalon | No | Was Cat 2 Sept 2023; removed April 15 2026; PCAC review July 23-24 2026; not lawfully compoundable | None — no manufacturer in late-stage development | None among major operators | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Named in Tailor Made DOJ plea. Russian-origin anti-aging peptide; FTC substantiation risk on anti-aging claims is high. |
| 11. GLOW (GHK-Cu + BPC-157 + TB-500) | No | Inherits worst member: BPC-157 + TB-500 are July 2026 PCAC; injectable GHK-Cu is Feb 2027 PCAC; not lawfully compoundable | None — no manufacturer in late-stage development | None — no major operator sells this combo via Rx | TIER 2-DEFERRED — only after BOTH July 2026 + Feb 2027 PCAC outcomes are favorable AND downstream FDA rulemaking for ALL three components | Two PCAC cycles + multiple rulemakings before this combo becomes lawful. Topical-GHK-Cu-only GLOW formulation MIGHT pre-date Feb 2027 if BPC-157 + TB-500 clear July 2026 PCAC. |
| 12. K-L-O-W (KPV + GHK-Cu + BPC-157 + TB-500 typical) | No | Inherits worst: KPV + BPC-157 + TB-500 are July 2026 PCAC; injectable GHK-Cu is Feb 2027 PCAC; not lawfully compoundable | None — no manufacturer in late-stage development | None — only research-peptide vendors (RUO) sell this combo | TIER 2-DEFERRED — same constraint as GLOW; composition genuinely varies by source — flag in formulary as ambiguous | Composition non-standard across vendors. Selling a non-standard combo via Rx adds independent essentially-a-copy ambiguity risk. |
| 13. CJC-1295 | No | Was Cat 2 Sept 2023; REMOVED Sept 27 2024 via Evexias settlement; NEVER placed on Cat 1; PCAC reviewed Dec 4 2024 but no subsequent rulemaking; PERMANENT LIMBO | None — no manufacturer in late-stage development | Tactus Health REFUSES to prescribe; no major operator sells | TIER 3 — HIGH-RISK, defensible only with extraordinary documented patient-specific clinical justification — RECOMMENDED SKIP | Named in Tailor Made DOJ plea Oct 2020. Growth-hormone-secretagogue FTC marketing exposure is highest enforcement category. |
| 14. Ipamorelin | No | Was Cat 2 Sept 2023 (as ipamorelin acetate); REMOVED Sept 27 2024 via Evexias; NEVER placed on Cat 1; PCAC reviewed Oct 29 2024 but no subsequent rulemaking; PERMANENT LIMBO | None — no manufacturer in late-stage development | Tactus Health REFUSES to prescribe; no major operator sells | TIER 3 — HIGH-RISK, defensible only with extraordinary documented patient-specific clinical justification — RECOMMENDED SKIP | Named in Tailor Made DOJ plea Oct 2020. Same regulatory profile as CJC-1295. Often paired with CJC-1295 as 'CJC-Ipa' growth hormone stack. |
| 15. Tesamorelin | YES — Egrifta (Theratechnologies), application number 022505 (BLA) approved Nov 10 2010 + Egrifta WR (F8 formulation) sBLA approved March 2025 | Two approved branded versions exist; compounding triggers essentially-a-copy under 503A(b)(1)(D) against BOTH formulations | Theratechnologies has manufacturer-litigation standing | None — no major peptide-wellness operator sells (HIV-lipodystrophy indication is narrow) | BRANDED RX ONLY — if any patient qualifies for HIV-lipodystrophy indication, dispense Egrifta WR; otherwise FULLY AVOID — never compound | Off-label tesamorelin for general body-composition / anti-aging is triple risk: essentially-a-copy + FDA off-label promotion + FTC anti-aging substantiation. |
| 16. GLP-3 / Retatrutide | No (not yet) — Eli Lilly Phase 3 TRIUMPH program; NDA filing targeted Q4 2026; potential approval 2027 | Not on any FDA bulks list; would become essentially-a-copy on Lilly filing | Eli Lilly — active manufacturer litigation precedent (Lilly v. Mochi/Henry/Willow/Fella April 2025); retatrutide will inherit and exceed tirzepatide enforcement intensity | None — no major operator sells compounded retatrutide via Rx; only RUO vendors offer it | FULLY AVOID — Phase 3 manufacturer + imminent FDA filing + Lilly's demonstrated willingness to litigate compounders | 'GLP-3' is colloquial; retatrutide is GLP-1/GIP/glucagon TRIPLE agonist. Selling 'GLP-3' as a category name itself is an FDA/FTC enforcement attractor. |
| 17. Semax | No | Was Cat 2 Sept 2023; removed April 15 2026; PCAC review July 23-24 2026; not lawfully compoundable | None — no manufacturer in late-stage development | Smaller specialty clinics (Better Med Spa, Iowa IV, Nava Health) — no major national operator | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Russian-origin nootropic; cognitive-claim marketing carries FTC substantiation risk. Named in Tailor Made DOJ plea. |
| 18. Selank | No | Was Cat 2 Sept 2023; REMOVED Sept 27 2024 via Evexias; NEVER placed on Cat 1; NOT on July 2026 PCAC NOR Feb 2027 PCAC; DEEPER LIMBO than CJC-1295/Ipamorelin | None — no manufacturer in late-stage development | Smaller specialty clinics (Better Med Spa, Iowa IV, Nava Health) — no major national operator | RUO-OR-SKIP — RECOMMEND SKIP — no FDA review timeline + RUO pretextuality enforcement makes both paths untenable | Named in Tailor Made DOJ plea. Cognitive-claim FTC risk. The only path forward would be a new sponsor nominating for FDA review from scratch. |
| 19. PT-141 (Bremelanotide) | YES — Vyleesi (Palatin Technologies), NDA 210557, approved June 21 2019 — premenopausal HSDD | Approved branded version exists; compounding triggers essentially-a-copy under 503A(b)(1)(D) | Palatin Technologies has manufacturer-litigation standing | Tactus Health prescribes PT-141 as one of its TWO sole peptides (sermorelin being the other) — but does so via patient-specific framing | BRANDED RX ONLY — prescribe Vyleesi for the HSDD indication. AVOID compounding bremelanotide outside that indication | Tactus's approach (PT-141 with patient-specific clinical justification framing) is the cleanest market precedent; even Tactus is the only major operator that touches PT-141. |
| 20. Melanotan 1 (Afamelanotide) | YES — Scenesse (Clinuvel Pharmaceuticals), NDA 210797, approved Oct 8 2019 — erythropoietic protoporphyria (EPP) | Approved branded version exists; compounding triggers essentially-a-copy under 503A(b)(1)(D) | Clinuvel has manufacturer-litigation standing | None — no major operator sells Melanotan 1 (Scenesse requires implant procedure) | BRANDED RX ONLY (and impractical for general telehealth) — FULLY AVOID for any peptide-wellness venture; Scenesse is a 16mg controlled-release implant, not a self-injection product | Common confusion: Melanotan 1 (Scenesse) is FDA-approved but practically impossible for telehealth; Melanotan 2 is the unapproved/banned product. |
| 21. Melanotan 2 | No — never approved | Pending Feb 2027 PCAC review; FDA enforcement since 2007 warning letter to Melanocorp | UK MHRA BANNED 2019; Australia TGA $101,412 in infringement notices; ongoing FDA enforcement | None — no major operator sells; only black-market and RUO vendors | FULLY AVOID — international ban precedent + FDA enforcement history + pending PCAC | Even if Feb 2027 PCAC is favorable, the UK/Australia ban precedent creates ongoing brand-perception drag for any US compounder. |
| 22. DSIP (Delta Sleep-Inducing Peptide) | No | Was Cat 2 Sept 2023 (as Emideltide); removed April 15 2026; PCAC review July 23-24 2026 (as DSIP/Emideltide); not lawfully compoundable | None — no manufacturer in late-stage development | None among major operators | TIER 2 — add only after favorable July 2026 PCAC + downstream FDA rulemaking | Named in Tailor Made DOJ plea. Same regulatory clock as BPC-157, TB-4, KPV, MOTS-C, Semax, Epitalon. User's brief categorization of DSIP as 'never on any list' was incorrect. |
Does this peptide have an FDA-approved branded version (check Drugs@FDA + Orange Book)?
Run this 10-item checklist on EVERY peptide before adding it to the venture's catalog. Failing any item should block catalog inclusion. Re-run annually — FDA bulks-list status, PCAC outcomes, manufacturer pipelines, and operator precedents change quarterly.
- Verify FDA approval status via Drugs@FDA + Orange Book — if an FDA-approved branded version exists, route to BRANDED RX ONLY analysis; do not include compounded form.
- Verify current 503A bulks-list status via FDA Federal Register notices — confirm whether on Category 1, Category 2, removed-from-Cat-2-pending-PCAC, or never-on-any-list. Re-verify quarterly.
- Verify no active manufacturer Phase 3 / pre-approval pipeline via clinicaltrials.gov + manufacturer IR pages — if any peer molecule is in active development, treat the entire family as high-risk.
- Document patient-specific clinical-justification SOP — verify the prescribing physician has a written, charted protocol BEFORE the Rx is written; cost savings explicitly does not qualify per FDA April 2026 clarification.
- Confirm the pharmacy partner does NOT source via salt-form API and obtain written attestation in the supply agreement.
- Confirm payment processor underwriting covers the specific peptide via MCC and LegitScript Healthcare Merchant Certification — do not assume coverage based on general telehealth approval.
- Confirm medical-malpractice carrier underwriting covers the specific peptide as an endorsement — disclose every peptide in the underwriting questionnaire; carriers exclude unapproved medications by default.
- Confirm at least one comparable major operator (Eden, Mochi, Henry, Good Life, Tactus, MEDVi, Willow, Noom, Ro) sells this peptide via Rx — if NO major operator sells it via Rx (only RUO vendors), that's a strong red flag worth legal-counsel review before adding.
- Confirm no warning letter or DOJ enforcement against this specific peptide in the last 24 months — search FDA warning letter database + DOJ press releases for the peptide name; the Tailor Made plea covers 14 peptides on the user's list including BPC-157, CJC-1295, DSIP, Epitalon, Ipamorelin, Melanotan II, Selank, Semax.
- Document the patient consent + risk-disclosure language in the intake flow — every patient receives the FDA-required 'this compounded product is not FDA-reviewed or approved for safety, effectiveness, or quality' disclosure BEFORE the Rx is written.
- Set 90-day calendar review for FDA + PCAC outcomes specific to this peptide (July 23-24 2026 PCAC for BPC-157/TB-4/KPV/MOTS-C/DSIP/Semax/Epitalon; Feb 2027 PCAC for injectable GHK-Cu/Melanotan II; Lilly retatrutide NDA-filing watch).
- Annual re-verification of EVERY checklist item — status changes are frequent in this space; treat catalog inclusion as a renewable license, not one-time decision.
Open questions
Things this report could not resolve. Send these to your specific advisor.
What will be the outcome of the July 23-24 2026 PCAC review of BPC-157, TB-4/TB-500, KPV, MOTS-C, DSIP/Emideltide, Semax, and Epitalon — and how long after a favorable PCAC recommendation will FDA take to translate that into Category 1 placement via rulemaking? Window 12-36 months per FDA Law Blog characterization.
Email this question to your lawyerWhat will be the outcome of the February 2027 PCAC review of injectable GHK-Cu and Melanotan II — and would a favorable outcome on Melanotan II actually re-open a US-only compounding pathway given the UK MHRA 2019 ban and Australia TGA enforcement?
Email this question to your lawyerIs there any operator currently selling K-L-O-W or KLOW blends as a documented patient-specific 503A compound (rather than via RUO research vendor)?
Email this question to your lawyerWhat is Eli Lilly's actual NDA submission timeline for retatrutide? Q4 2026 is analyst projection; Lilly has not officially announced. The peptide-as-essentially-a-copy attack vector becomes live the moment Lilly files.
Email this question to your lawyerDoes the user's stated 'GLP-3' marketing terminology create independent FTC / FDA exposure given that 'GLP-3' is not a recognized drug class?
Email this question to your lawyerIs Selank salvageable under any future FDA pathway? It was removed from Category 2 in September 2024 alongside CJC-1295 and ipamorelin but was NOT included on either the July 2026 or February 2027 PCAC agenda. Selank is in deeper permanent limbo than CJC-1295/ipamorelin.
Email this question to your lawyer